04/14/2025 7:24 AM | Karyopharm Therapeutics (Filer)
| Form ARS | |
04/14/2025 7:15 AM | Karyopharm Therapeutics (Filer)
| Form DEF 14A | |
04/14/2025 7:19 AM | Karyopharm Therapeutics (Filer)
| Form DEFA14A | |
04/10/2025 4:23 PM | Affinity Asset Advisors, LLC (Filed by) Karyopharm Therapeutics (Subject)
| Form SCHEDULE 13G | |
03/06/2025 3:13 PM | Karyopharm Therapeutics (Issuer) Mano Michael (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/04/2025 3:48 PM | Karyopharm Therapeutics (Issuer) Paulson Richard A. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/04/2025 3:49 PM | Abate Kristin (Reporting) Karyopharm Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/04/2025 3:46 PM | Karyopharm Therapeutics (Issuer) Mano Michael (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/19/2025 6:32 AM | Karyopharm Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
02/19/2025 6:36 AM | Karyopharm Therapeutics (Filer)
| Form 10-K Annual report pursuant to Section 13 or 15(d) | |
02/12/2025 8:36 AM | Adage Capital Management, L.P. (Filed by) Karyopharm Therapeutics (Subject)
| Form SCHEDULE 13G | |
Get the Latest News and Ratings for KPTI and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Karyopharm Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
|
02/05/2025 3:16 PM | Karyopharm Therapeutics (Issuer) Paulson Richard A. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/13/2025 7:34 AM | Karyopharm Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
01/07/2025 3:03 PM | Karyopharm Therapeutics (Issuer) Paulson Richard A. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/06/2025 4:07 PM | Karyopharm Therapeutics (Issuer) Macomber Lori (Reporting)
| Form 3 Initial statement of beneficial ownership of securities | |
01/02/2025 6:08 AM | Karyopharm Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
12/05/2024 3:35 PM | Karyopharm Therapeutics (Filer)
| Form PRE 14A | |
12/05/2024 3:15 PM | Karyopharm Therapeutics (Issuer) Paulson Richard A. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
12/03/2024 6:09 AM | Karyopharm Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
11/12/2024 2:50 PM | Karyopharm Therapeutics (Subject) VANGUARD GROUP INC (Filed by)
| Form SC 13G/A | |
11/06/2024 3:06 PM | Karyopharm Therapeutics (Issuer) Paulson Richard A. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
11/05/2024 7:02 AM | Karyopharm Therapeutics (Filer)
| Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
11/05/2024 6:47 AM | Karyopharm Therapeutics (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
11/05/2024 6:41 AM | Karyopharm Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
11/04/2024 10:49 AM | Karyopharm Therapeutics (Subject) VANGUARD GROUP INC (Filed by)
| Form SC 13G/A | |
10/31/2024 6:41 AM | Karyopharm Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
10/25/2024 8:30 AM | HIGHBRIDGE CAPITAL MANAGEMENT LLC (Filed by) Karyopharm Therapeutics (Subject)
| Form SC 13G | |
09/05/2024 3:28 PM | Karyopharm Therapeutics (Issuer) Mano Michael (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
09/05/2024 3:13 PM | Cheng Sohanya Roshan (Reporting) Karyopharm Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
09/05/2024 3:24 PM | Karyopharm Therapeutics (Issuer) Mason Michael (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
09/05/2024 3:26 PM | Karyopharm Therapeutics (Issuer) Paulson Richard A. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
08/29/2024 3:05 PM | Karyopharm Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
08/08/2024 3:31 PM | Karyopharm Therapeutics (Issuer) Paulson Richard A. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
08/06/2024 6:33 AM | Karyopharm Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
08/06/2024 6:42 AM | Karyopharm Therapeutics (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
07/31/2024 3:14 PM | Karyopharm Therapeutics (Issuer) Poulton Stuart (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
07/19/2024 3:07 PM | Karyopharm Therapeutics (Subject)
| Form SC TO-I/A | |
07/09/2024 3:15 PM | Karyopharm Therapeutics (Issuer) Paulson Richard A. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
07/08/2024 3:32 PM | BlackRock Inc. (Filed by) Karyopharm Therapeutics (Subject)
| Form SC 13G/A | |
06/20/2024 7:01 AM | Karyopharm Therapeutics (Subject)
| Form SC TO-I | |
06/09/2024 11:15 PM | Karyopharm Therapeutics (Filer)
| Form EFFECT | |
Trump and Musk fight back (Ad) Is there more to the Musk–Trump relationship than meets the eye?
Jeff Brown thinks so — and he believes it has to do with a top-level initiative to build the ultimate military-grade AI system. He’s calling it the “AI Superweapon,” and he says it could soon become the center of global tech dominance.
At the core of this initiative? A handful of companies tied to America’s most powerful tech platforms — and investors who act before this goes mainstream may have a rare early edge. Click here to see why Jeff believes this is the biggest stock story of the year — and which companie |
06/07/2024 6:18 PM | Karyopharm Therapeutics (Issuer) PAKIANATHAN DEEPIKA (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/04/2024 5:51 PM | Karyopharm Therapeutics (Issuer) PAKIANATHAN DEEPIKA (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
05/31/2024 7:00 AM | Karyopharm Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
05/30/2024 4:32 PM | Karyopharm Therapeutics (Issuer) Oliger Christy J. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
05/30/2024 4:19 PM | BOHLIN GAREN G (Reporting) Karyopharm Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
05/30/2024 4:25 PM | Greene Barry E (Reporting) Karyopharm Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
05/30/2024 4:32 PM | Karyopharm Therapeutics (Issuer) Mirza Mansoor Raza (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
05/30/2024 4:32 PM | Karyopharm Therapeutics (Issuer) PAKIANATHAN DEEPIKA (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
05/30/2024 4:32 PM | Karyopharm Therapeutics (Issuer) Schor Chen (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
05/30/2024 4:32 PM | Karyopharm Therapeutics (Issuer) Su Zhen (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
05/30/2024 3:44 PM | Karyopharm Therapeutics (Filer)
| Form S-3 Registration statement under Securities Act of 1933 | |
05/14/2024 3:06 PM | Karyopharm Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
05/08/2024 3:13 PM | Karyopharm Therapeutics (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
05/08/2024 6:47 AM | Karyopharm Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
05/08/2024 6:52 AM | Karyopharm Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
05/07/2024 3:56 PM | Karyopharm Therapeutics (Issuer) Paulson Richard A. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |